Gilead, Merck’s HIV experimental drug scores ‘high’ on viral suppression
Merck & Co., Inc., and Gilead Sciences, Inc.’s investigational combinational drug for HIV treatment, put on clinical hold last year, has met a.
Drugs
Health
Pharma
Drugs
Medical
Pharma
USFDA puts on hold influenza, Covid-19 trial vaccines of Novavax
Novavax, Inc.’s mid-stage trials on a combination of Covid-19 and influenza and a standalone influenza vaccine have been put on hold by the.
Drugs
Health
Pharma
Pfizer’s drug to treat rare haemophilia disorder gets US regulator’s approval
Pfizer Inc., got a nod from the US drug regulator for its drug Hympavzi to treat two types of a rare blood disorder.
Drugs
Health
Pharma
Sage Therapeutics halts trials of experimental drug to treat dementia
Sage Therapeutics Inc.’s experimental drug failed to meet its main goal of treating mild dementia due to Alzheimer's disease and the US, Cambridge-headquartered.
Drugs
Health
Medical
J&J stops trials on drug to treat muscle-invasive bladder cancer
Johnson and Johnson discontinued a study of an investigational drug to treat bladder cancer after it failed to yield desired results
Drugs
Health
Pharma
Gilead signs six global pacts to make, sell generic HIV preventive drug
Gilead Sciences, Inc. has signed non-exclusive, royalty-free voluntary licensing agreements with six pharmaceutical makers to make and sell its generic lenacapavir drug for the prevention.
Drugs
Health
Medical
Lilly to invest $4.5 billion to build Medicine Foundry in Indiana state, US
Eli Lilly and Company will build a $4.5 billion center for advanced manufacturing and drug development in Indiana to innovate new production methods.
Drugs
Health
Pharma
Amplifica’s human trial medicine for hair growth shows 15% more efficacy
Amplifica Holdings Group Inc.’s first-in-human trial of an injectable medicine for treating hair loss has shown a more than 15% increase in non-vellus.
Drugs
Health
Pharma
Merck’s trial drug combination for colorectal cancer fails main goal
Merck & Co., announced its trial drug along with a combination of the company’s Keytruda therapy failed to meet the main goal of.
Drugs
Health
Pharma
Amgen’s trial drug to fight autoimmune disorder improves patient outcomes
Amgen Inc.’s experimental drug to treat patients suffering from a rare muscle-weakening disease, myasthenia gravis, has shown positive results in an end-stage trial.